<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279903</url>
  </required_header>
  <id_info>
    <org_study_id>1565-05</org_study_id>
    <nct_id>NCT00279903</nct_id>
  </id_info>
  <brief_title>Is Botox Effective in Relieving Pain From Knee Osteoarthritis?</brief_title>
  <official_title>Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with painful knee osteoarthritis will be randomly allocated to one of three groups.&#xD;
      Each group will receive a knee injection of: 1) cortisone, 2) low dose Botox, or 3) high dose&#xD;
      Botox. Patients will then be followed for 6 months to see if they have significant pain&#xD;
      relief or improvement in their activity level after the injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract Botulinum toxin type A (Btx-A) has been extensively studied and used clinically for&#xD;
      its muscle paralyzing effects, but there is a growing body of evidence to support a role in&#xD;
      pain modulation. Symptomatic osteoarthritis is a leading cause of pain, functional&#xD;
      impairment, and disability, with significant indirect costs to society. Preliminary evidence&#xD;
      suggests that Btx-A has a significant nociceptive effect, when injected intra-articularly, in&#xD;
      to painful joints. The proposed study will evaluate the efficacy and safety of Btx-A injected&#xD;
      intra-articularly in 60 subjects with moderate pain and functional impairment secondary to&#xD;
      knee osteoarthritis, in a randomized, cortisone-controlled, double blind study, over a 6&#xD;
      month follow up period. If Btx-A is shown to be of equal or greater efficacy than cortisone&#xD;
      in this patient population, it may be an excellent second line treatment for osteoarthritis,&#xD;
      in multiple joints, where surgery is contraindicated or deferred due to age, comorbidities,&#xD;
      or patient preference. Further studies examining the mechanism of action at the biochemical&#xD;
      level, the clinical effect of Btx-A in other joints (in both osteoarthritis and inflammatory&#xD;
      arthritis), the efficacy of Btx-A compared to hyaluronic acid (the only currently available&#xD;
      injectable alternative to cortisone), and the side effect profile (effect on adjacent muscle&#xD;
      strength, joint position sense, and long-term outcomes) would be indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in pain at 8 weeks post injection</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in function at 2, 4, 8, 12, 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life at 2, 4, 8, 12, 26 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in pain at 2, 4, 12, 26 weeks</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Cortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Btx-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Btx-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A (Btx-A)</intervention_name>
    <description>Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.</description>
    <arm_group_label>High Dose Btx-A</arm_group_label>
    <arm_group_label>Low Dose Btx-A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortisone</intervention_name>
    <description>1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.</description>
    <arm_group_label>Cortisone</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. A history of knee joint pain for greater than 6 months.&#xD;
&#xD;
          2. Medial or lateral tibiofemoral joint line tenderness.&#xD;
&#xD;
          3. Unilateral knee pain 6/10 or greater, on average, on the visual analog scale (VAS),&#xD;
             that interferes with function most days per week.&#xD;
&#xD;
          4. Prior failed treatment with acetaminophen and/or non steroidal anti-inflammatory&#xD;
             medications, and physical therapy (quadriceps strengthening).&#xD;
&#xD;
          5. Kellgren grade II or III radiographic changes of osteoarthritis.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Age less than 40 years.&#xD;
&#xD;
          2. Anticoagulation with warfarin or heparin.&#xD;
&#xD;
          3. Known allergy or sensitivity to any of the components of the study medications.&#xD;
&#xD;
          4. Body mass index greater than 35.&#xD;
&#xD;
          5. Previous major reconstructive surgery on the affected knee.&#xD;
&#xD;
          6. Previous arthroscopic surgery on the affected knee in the past 12 months.&#xD;
&#xD;
          7. History of crystal induced arthropathy.&#xD;
&#xD;
          8. Use of aminoglycoside antibiotics, curare-like agents, or history of neuromuscular&#xD;
             disease such as myasthenia gravis, amyotrophic lateral sclerosis, or myopathy.&#xD;
&#xD;
          9. History of or evidence of active rheumatologic disease, diabetes, severe peripheral&#xD;
             neuropathy, clinically evident cardiac or respiratory disease that interferes with&#xD;
             functional status, or other serious diseases, including psychiatric disorders.&#xD;
&#xD;
         10. Evidence of recent alcohol or drug abuse, or history of medication misuse or&#xD;
             addiction.&#xD;
&#xD;
         11. Females who are pregnant, breastfeeding, or planning a pregnancy during the study, or&#xD;
             who think that they may be pregnant at the start of the study, or females of&#xD;
             childbearing potential who are unable or unwilling to use a reliable form of&#xD;
             contraception during the study.&#xD;
&#xD;
         12. Intra-articular (knee) or systemic steroids in the past 6 months, or intra-articular&#xD;
             knee hyaluronic acid injection in the past 6 months.&#xD;
&#xD;
         13. Patients who rate their average daily pain as less than 6 on a 10 point VAS scale at&#xD;
             the screening visit.&#xD;
&#xD;
         14. Concurrent participation in another investigational drug or device study or&#xD;
             participation in the 30 days immediately prior to study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea J. Boon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2006</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

